Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease
rosiglitazone
AVA100193
Alzheimer's Disease
Phase 2
 
A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013

Powered by ideaPoint, Inc.